EPRX Eupraxia Pharmaceuticals, Inc.: Enterprise Value to EBITDA Ratio
Eupraxia Pharmaceuticals focuses on developing extended-release injections, including arthritis treatments designed for long-term patient comfort. The business relies on an autonomous production cycle, which renders the asset independent of global crises and transforms it into a defensive asset. This price chart on GURU.Markets demonstrates an EV/EBITDA of 0.00, highlighting the company's potential in the modernization of polymer microspheres for targeted drug delivery.
Comprehensive metric breakdowns and analytics for Eupraxia Pharmaceuticals Inc. (EPRX)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Eupraxia Pharmaceuticals|EPRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Eupraxia Pharmaceuticals Inc.|EPRX - Company Cumulative Debt|Debt to Book Value Eupraxia Pharmaceuticals|EPRX - Company Long-Term Debts|Company Short-Term Debt Eupraxia Pharmaceuticals|Quick Liquidity eupraxiapharma.com
- financial results and valuation multiples details:
EPRX - Final Profit|Projected Future Earnings Eupraxia Pharmaceuticals|EPRX - P/E Multiple|Projected Price to Earnings eupraxiapharma.com|EPRX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Eupraxia Pharma|EPRX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Eupraxia Pharmaceuticals|EPRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months eupraxiapharma.com|EPRX - Earnings per share increase in current year|Net earnings per share growth forecast for next year Eupraxia Pharmaceuticals
- company sales and revenue statistics:
Initial company analysis:Eupraxia Pharmaceuticals (EPRX)
The stability of Eupraxia Pharmaceuticals (EPRX) relies on a highly skilled R&D staff and innovations in targeted drug delivery. The EV/EBITDA metric correlates the total enterprise value, including net debt, with its operating profit before taxes. It is critical for investors to determine whether the current market price justifies the startup's potential for a technological breakthrough. By analyzing the EV/EBITDA ratio of Eupraxia Pharmaceuticals (EPRX) within a historical context, one can identify whether the asset is currently overvalued or undervalued.
Competitors of Eupraxia Pharmaceuticals
Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Theravance Biopharma Inc (TBPH)|AQST (aquestive.com) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding Corp. - Enterprise Value to Operating Income Before Depreciation|China SXT Pharmaceuticals - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|invizyne.com - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ORMP (Oramed Pharmaceuticals Inc.)|ENTX: EV/EBITDA Multiple|MindWalk Holdings Inc. (HYFT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to Operating Income Before Depreciation CPIX (Cumberland Pharmaceuticals Inc.)|EV/EBITDA Multiple QNTM|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Corporation|EV/EBITDA Multiple TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|SNYR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio
